In vitro inhibition of binding of tumor necrosis factor (TNF)-alpha by monoclonal antibody to TNF receptor on glioma cell and monocyte.
The use of monoclonal antibodies to the tumor necrosis factor (TNF) receptors, the TNF-p55 receptor (TNF-p55R) and the TNF-p75 receptor (TNF-p75R), was evaluated to reduce the effects of TNF caused by binding to TNF-p75R. Competitive binding of anti-TNF-p55R (mAbp55R) and anti-TNF-p75R monoclonal antibodies (mAbp75R) with iodine-125-labeled TNF-alpha to GL-9 glioma cells and U937 histiocytic lymphoma cells was evaluated. The effects of mAbp55R and mAbp75R on the growth suppression by TNF-alpha of GL-9 cells and TNF-alpha production in U937 cells were also examined. mAbp75R bound to U937 cells competitively with TNF-alpha and suppressed TNF-alpha production by U937, but had no effect on the growth inhibition of GL-9 human glioma cell by TNF-alpha in vitro. These findings suggest that co-administration of TNF-p75R antagonist with TNF-alpha may decrease the toxicity of TNF-alpha administration resulting in a better therapeutic result.